Sodium-glucose co-transporter 2 inhibitor treatment and risk of atrial fibrillation: Scandinavian cohort study

<p>  </p> <p><em>Objective</em>: To assess the association between use of SGLT2 inhibitors and the risk of new-onset AF in routine clinical practice.</p> <p><em>Research design and methods</em>: We used nationwide registers in Denmark, Norway and Sweden, 2013-2018, to include patients without history of AF who were newly prescribed an SGLT2 inhibitor or an active comparator (glucagon-like peptide-1 [GLP-1] receptor agonist). We performed a cohort study to assess new-onset AF in intention-to-treat analyses using Cox regression, adjusted for baseline covariates with propensity score weighting.</p> <p><em>Results</em>: We identified 79343 new users of SGLT2 inhibitors (59.2% dapagliflozin, 40.0% empagliflozin, 0.8% canagliflozin and <0.1% ertugliflozin) and 57613 new users of GLP-1 receptor agonists. Mean age of the study cohort was 61 years and 60% were men. The adjusted incidence rate of new-onset AF was 8.6 per 1000 person-years for new users of SGLT2 inhibitors as compared with 10.0 per 1000 person-years for new users of GLP-1 receptor agonists. The adjusted hazard ratio (aHR) was 0.89 (95% CI 0.81-0.96) and the rate difference was 1.4 fewer events per 1000 person-years (95% CI 0.6-2.1). Using an as-treated exposure definition, the aHR for new-onset AF was 0.87 (95% CI 0.76-0.99). No statistically significant heterogeneity of the aHRs was observed between subgroups of patients with and without a history of heart failure or major cardiovascular disease. </p> <p><em>Conclusions</em>: In this cohort study using nationwide data from three countries, use of SGLT2 inhibitors as compared with GLP-1 receptor agonists, was associated with a modestly reduced risk of new-onset AF.</p>